ArticleJournal of hepatocellular carcinoma2026
Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a complex disease best managed through multidisciplinary care, yet real-world patterns of medical specialty involvement remain poorly characterized. This study mapped specialty care pathways for HCC patients treated at the three Mayo Clinic destination medical centers. Methods: A retrospective review was performed using the Mayo Data Explorer for treatments delivered between May 2020 and May 2025. Patients with HCC were identified through diagnosis codes or hepatology consultation. Therapeutic events across interventional radiology (IR), medical oncology, transplant surgery, radiation oncology, and hepatopancreatobiliary surgery (HPBS) were analyzed descriptively by treatment line and Barcelona Clinic Liver Cancer (BCLC) stage. Results: Of 6051 HCC patients identified, 4799 met inclusion criteria. Hepatology provided consultation for 87% of patients (n=4183). For first-line treatments (n=3079), 37% received initial therapy from IR, 27% from medical oncology, 17% from transplant surgery, 10% from HPBS, and 9% from radiation oncology. IR remained the most common provider across subsequent treatment lines. Analyses were based on treatment events, and some patients contributed to multiple treatment lines. Among patients with documented BCLC stage (n = 906), IR most frequently delivered initial therapy for stages 0 and A, whereas medical oncology predominated for stages B and C. Locoregional therapies were used in 27% of BCLC C patients. Conclusion: This real-world mapping reveals IR as a procedural cornerstone within multidisciplinary HCC management, particularly for early-stage disease. Hepatology remains essential for initial patient evaluation and care coordination. Medical oncology predominates for intermediate-stage disease, while locoregional therapy continues to be used in a substantial proportion of advanced-stage cases. These findings highlight the complex and evolving role of subspecialties in the management of HCC and may inform future resource allocation and care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.